key: cord-0864821-sfx4ka1z
authors: Suwanwongse, Kulachanya; Shabarek, Nehad
title: Clinical features and outcome of HIV/SARS‐CoV‐2 coinfected patients in The Bronx, New York city
date: 2020-06-09
journal: J Med Virol
DOI: 10.1002/jmv.26077
sha: eeae5499e34feeb1e0a6bec81106ad3e10871928
doc_id: 864821
cord_uid: sfx4ka1z

Coronavirus disease 2019 (COVID-19) is a highly contagious disease with millions of people have been infected. However, there is limited data regarding clinical features, disease courses and outcomes of COVID-19 in patients with human immunodeficiency virus (HIV). Herein, we presented the demographic data, clinical characteristics and outcomes of nine confirmed COVID-19 patients with HIV infection admitted to our hospital located in south Bronx, New York City. Our study revealed very high mortality rate at 78%, which may contradict to the hypothesis that immunosuppression from HIV infection prevents against severe COVID-19. More research is needed to determine the impact of HIV on the clinical course of COVID-19. This article is protected by copyright. All rights reserved.

To the Editor, Currently, coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a public health crisis, with almost five million people have been infected and of which more than 300 000 died. 1 Older ages and several comorbidities, such as hypertension, diabetes mellitus, and cardiovascular diseases, are identified as risk factors for developing severe COVID-19 and deaths. 2, 3 It is estimated that 40 million people worldwide have human immunodeficiency virus (HIV) infection. 4 Thus, we are expecting to encounter a significant number of patients with HIV with SARS-CoV-2 infection. However, there is limited evidence regarding the impact of HIV infection on the severity and mortality related to COVID-19. Several case reports and case series showed that the mortality and severity of COVID-19 were not increased in patients with HIV. [5] [6] [7] In contrast, HIV/SARS-CoV-2 coinfected patients may have mortality benefits from the immunosuppressive state. 8 However, the data from our institution showed contradictory results. Herein, we presented the case series of hospitalized HIV patients with COVID-19 in a single hospital in the South Bronx, the area that is well known for its most poverty, least education, highest criminal, and poorest health outcomes in New York. The clinical features and outcomes of nine HIV/SARS-CoV-2 coinfected patients admitted to our hospital from 25 March to 20

April 2020 are discussed. Table 1 provides demographic data, clinical features, and outcomes of each patient. The median age of the patients was 58 years old (range, 31-76). Seven were males and two were females. All patients had multiple comorbidities. The diagnosis of COVID-19 was confirmed by a positive SARS-CoV-2 RT-PCR test from nasopharyngeal swab specimens. Most recent patients CD4+ T cell count ranged from 179 to 1827 per mm 3 . HIV viral load was very low to undetectable. Eight patients were on highly active antiretroviral therapy (HAART), of which six reported medication compliances.

HAART was discontinued during hospital admission in four patients, two of which was due to acute kidney injury (AKI), and the other two were for an unclear reason. Fever, cough, and dyspnea were the most common presenting symptoms among all patients. One patient initially presented with gastrointestinal tract symptoms, including nausea, vomiting, and watery diarrhea. Chest X-ray (CXR) abnormalities compatible with COVID-19 pneumonia were found in eight patients (89%) and correlated with disease severity. All patients' Abbreviations: AF, atrial fibrillation; ATV, atazanavir; AZ, azithomycin; Cef-3, ceftriaxone; COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease-2019; CRP (mg/dL), C-reactive protein; CXR, chest X-ray; DD (ng/mL), D-dimer; doxy, doxycycline; DRV, darunavir; DTG, dolutegravir; EVG, elvitegravir; EFV, efavirenz; FER (mg/dL), ferritin; FTC, emtricitabine; HCV, hepatitis C infection; HCQ, hydroxychloroquine; HF, heart failure; HLD, hyperlipidemia; HTN, hypertension; IL6 (pg/mL), interleukin-6; LOS, length of stay; PEEP, positive end-expiratory pressure; RAL, raltegravir; RSF, respiratory failure; RTV, ritonavir; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate; WBC, white blood cells.

COVID-19) Situation Report-119

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China

Fact Sheet: World AIDS Day 2019-Global HIV Statistics

COVID-19 in patients with HIV: clinical case series

COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients

Could HIV infection alter the clinical course of SARS-CoV-2 infection? When less is better

Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and metaanalysis

COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?

Benign course of COVID-19 in a multiple sclerosis patient treated with Ocrelizumab